Business News

    Botanix Pharmaceuticals (ASX:BOT) raises $10M via institutional placement

    Article Image

    Botanix Pharmaceuticals (ASX:BOT) has secured $10M through an institutional placement to launch its Sofpironium Bromide gel.

    The funds will be used to progress Botanix's lead programme, including satisfying milestone payments and preparing for commercial launch in the US.

    The placement comes after a recent mid-cycle review meeting, paving the way for Food and Drug Administration review and commercial readiness.

    The clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol's share price closed up 5% today.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa